A phase III trial published in 2001 demonstrated that CD34 selection using a Ceprate-R Stem Cell concentrator device resulted in a 3-log reduction in MM cells in the autografts, though this did not translate into improved PFS or OS [22, 23]. This evidence concerns the gene CD34 and Miyoshi myopathy.